Satisfactory screening for cystic fibrosis with the BM meconium procedure

RT EVANS,* AJ LITTLE,* AE STEEL,† JM LITTLEWOOD‡

From the *Departments of Clinical Biochemistry and †Paediatrics, St James’s University Hospital, Leeds, and the ‡Department of Clinical Biochemistry, Seacroft Hospital, Leeds

SUMMARY The Boehringer Mannheim test (BM test) for cystic fibrosis has been applied to 15 734 neonates. A positive result occurred in 130, seven of whom were subsequently shown to have the disease. To our knowledge no cases have been missed. Tests have been performed centrally by experienced laboratory staff and the false-positive rate of 0·83% is considered acceptable. It is important to follow up weak as well as strongly positive reactions to the BM test strip.

Cystic fibrosis (CF) is a serious inherited disorder affecting one infant in 2000 in this country. It is characterised by repeated chest infections, malabsorption secondary to pancreatic insufficiency and a raised salt content in the sweat. At the present time, the state of progression of the lung damage is a major factor in determining prognosis, although nutritional problems are becoming increasingly important as prolonged survival becomes more common.

There is now considerable evidence for improved duration and quality of life among children in whom the diagnosis has been made early, before progressive lung disease is advanced and the general condition compromised by nutritional deficiencies.1 Furthermore, comparisons of the fate of second siblings in whom the diagnosis has been made at birth, with the first sibling in the family, supports the advantages of early diagnosis.2 While potentially this could be effected by means of a neonatal screening programme, no method has so far been available which is free from unacceptably large numbers of both false-positive and -negative reactions.

One possible screening test for CF has been advocated based upon the presence of increased amounts of protein in meconium from affected infants.3–4 Since 1975 a commercially available purpose-made strip test—the BM meconium test combination (BM test)—has been widely used for this purpose. Authors have expressed different views as to the reliability of the test,5–7 but most agree that for 10% of CF infants with near normal or normal pancreatic function, a false-negative meconium test is likely. Such patients have been well documented.8

Our report describes the successful use of the BM test for screening 15 734 neonates over 4 years 3 months in a well-defined neonatal population.

Material and methods

Meconium specimens passed within the first 24 h were tested in the chemical pathology laboratory with the BM meconium test combination (Boehringer Corporation, Mannheim, GFR). Specimens were stored at 4°C if there was likelihood of delay before analysis. Any evidence at all of a blue coloration of the test strip was regarded as positive and an indication for further investigation.

All infants who had a positive BM meconium test had a sweat test within the first month of life and, whenever possible, a second six months later. Sweat electrolytes were measured following pilocarpine iontophoresis9 by senior laboratory staff widely experienced in the technique. Adequate sweat collections were not always achieved during the first week of life but use of the small of the back as the collection site invariably resulted in a successful outcome by the age of three weeks.

Occult blood tests were performed by the method of Crossley.10

The chymotryptic activity of meconium and faeces has been measured by monitoring the rate of hydrolysis of acetyl tyrosine ethyl ester at pH 7·8 in the presence of calcium and sodium chlorides as activators.11 Values found in normal infants lay within the range 80-1000 μg/g wet stool, the distribution of activities being non-gaussian.

The relative concentrations of albumin and α1 antitrypsin, the albumin:α1 antitrypsin ratio, in homogenates of meconium were measured by radial
immunodiffusion. A value of up to 2.0 is considered normal. This investigation was introduced late into the screening programme.

The detection of lactase activity in meconium has been based upon the qualitative demonstration of glucose following incubation of meconium with lactose. No activity is normally expected.

**Results**

Between October 1975 and 1 January 1980, 15,734 babies were screened. A positive BM test was found in 130 infants, seven of whom were diagnosed for CF. No BM test was performed on an eighth infant who died at the age of two days with meconium ileus. At necropsy the histological findings in pancreas, liver, and salivary glands were typical of CF.

Of the remaining 123 infants, 105 were subsequently shown not to have CF on the basis of normal progress, normal faecal chymotrypsin and sweat tests. Two sweat tests were performed on each of 75 infants while 30 had only a single test. Of 18 infants incompletedly evaluated, nine died soon after birth.

Eight false-positive results were associated with the presence of blood in the meconium (usually visible on inspection) and 19 with the presence of meconium "plug" material.

Lactase activity was demonstrated in no less than 29 of 79 specimens from infants who eventually proved to be normal.

**Discussion**

Of the seven CF infants detected in this series, three could have been identified as siblings of known patients or because of meconium ileus. However, in the remaining four there was no reason to suspect the diagnosis. As a direct result of the screening programme, prompt treatment and genetic advice were given.

**Findings in affected infants**

<table>
<thead>
<tr>
<th>Infant</th>
<th>BM test</th>
<th>Occult blood</th>
<th>Lactase</th>
<th>Albumin:a1 antitrypsin ratio</th>
<th>Faecal chymotrypsin (µg/g)</th>
<th>Sweat tests</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sodium</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Chloride</td>
</tr>
<tr>
<td>1</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>10, 12</td>
<td>175, 170</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>10</td>
<td>134, 132</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Weak</td>
<td>+</td>
<td>-</td>
<td>33</td>
<td>89, 120</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>20, 50</td>
<td>100, 109</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>12</td>
<td>114, 150</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>5, 10</td>
<td>134, 134</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>10-8</td>
<td>110, 140</td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>21, 5, 4, 5</td>
<td>164, 180</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3-2</td>
<td>88, 97</td>
<td></td>
</tr>
</tbody>
</table>

The detection rate is in keeping with the known frequency of the disease. Extensive enquiries to all the paediatricians in our region have, so far, failed to reveal any evidence of a missed patient from among the infants screened, but, since pancreatic function is alleged to be near normal in 10% of CF children, it is possible that this proportion will be missed by tests such as this which are based on meconium abnormalities. Other authors have reported a false-negative rate of up to 25%, but we believe that many of these poor results are due to the test being performed on wards by large numbers of inexperienced and uninvolved staff. We would emphasise the need for tests to be carried out centrally and by experienced laboratory workers.

We also regard as essential the full investigation of infants who give a weak-positive BM test. The acceptance of the manufacturer's definition that only a strong blue is indicative of a positive reaction would have resulted in our missing one of the present CF cases.

The test has been criticised because of an unacceptably high false-positive rate. In our hands, however, the frequency of false-positives was only 0.83%. We consider this acceptable although it necessitates evaluation of a significant number of unaffected infants and the parental anxiety engendered is a continuing problem. Up to the present time sweat tests and faecal chymotrypsin estimations combined with clinical assessment have allowed a reliable diagnosis to be established within a few weeks. The faecal chymotrypsin values have been particularly helpful (Table).

It is possible that in the future immunoreactive trypsin estimations on babies who have a positive BM test will allow an even more rapid evaluation.

We anticipate the false-negative rate of this screening programme to approach 10% with a false-positive rate of 0.8%. We believe that early diagnosis is important and that in the absence of a screening programme, diagnosis may be delayed
Satisfactory screening for cystic fibrosis with the BM meconium procedure

until infants have already had a number of chest infections and become severely compromised nutritionally. Early detection reduces parental anxiety and unhappiness during the prediagnosis phase and allows genetic advice to be given before they embark upon a further pregnancy. Until such time as a reliable, cheap alternative test is available we will continue to screen our infants with the BM test taking the precautions to perform the test in the laboratory and to evaluate even weak-positive reactions.

References


Requests for reprints to: Dr RT Evans, St James’ Hospital, University Hospital, Beckett Street, Leeds LS9 7TF, England.
Satisfactory screening for cystic fibrosis with the BM meconium procedure.
R T Evans, A J Little, A E Steel and J M Littlewood

doi: 10.1136/jcp.34.8.911

Updated information and services can be found at:
[http://jcp.bmj.com/content/34/8/911](http://jcp.bmj.com/content/34/8/911)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)